Compound brief
Evidence brief. Not treatment advice or a safety clearance. Last evidence update: September 2026.
Albumin binding slows clearance relative to native incretin hormones. Glucagon-receptor agonism is the chemical difference from tirzepatide.
It is not semaglutide with a higher milligram number. The receptor set is different.
GLP-1 and GIP receptor agonism increase glucose-dependent insulin secretion, slow gastric emptying, and reduce appetite. Glucagon receptor agonism adds hepatic energy expenditure signaling and is the reason heart-rate talk is louder than with a pure GLP-1 analog.
The phase 2 obesity trial recorded dose-dependent heart-rate rise that later eased, and gastrointestinal events as the common adverse events. A numeric glucose result was not extracted, so glucose lowering stays inferred class biology.
Forum themes are unverified. They do not outrank a study, and they are not a dose.
Incretin side-effect talk · unverified
Community logs emphasize nausea, fullness, heart-rate awareness, and stacking with other peptides during dose changes. Gastrointestinal events and a heart-rate rise also appear in the seeded phase 2 trial. Forum stacks do not add a new controlled interaction.
Theme summarized from public discussion. Not a quoted post, not a trial, and not a dose.